FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109290265> ?p ?o ?g. }

• W2109290265 endingPage "1107" @default.
• W2109290265 startingPage "1099" @default.
• W2109290265 abstract "OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs. METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline rCBV. Log-rank tests were used to evaluate the association of rCBV with survival and time to progression. Kaplan-Meier time-to-progression curves were generated. Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression. RESULTS: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable disease). Log-rank tests showed that rCBV exhibited a significant negative association with disease-free survival (P = 0.0015), such that low rCBV values were associated with longer time to progression. Kaplan-Meier curves demonstrated that lesions with rCBV less than 1.75 (n = 16) had a median time to progression of 4620 ± 433 days, and lesions with rCBV more than 1.75 (n = 19) had a median time to progression of 245 ± 62 days (P < 0.005). Lesions with low baseline rCBV (<1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (>1.75) demonstrated progressively increasing tumor volumes over time. CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation. This suggests that rCBV measurements may be used as a second reference standard to determine the surgical management/risk–benefit equation and postsurgical adjuvant therapy for LGGs." @default.
• W2109290265 created "2016-06-24" @default.
• W2109290265 creator A5014244649 @default.
• W2109290265 creator A5015059017 @default.
• W2109290265 creator A5021588104 @default.
• W2109290265 creator A5024526307 @default.
• W2109290265 creator A5026110145 @default.
• W2109290265 creator A5052171046 @default.
• W2109290265 creator A5053547123 @default.
• W2109290265 date "2006-06-01" @default.
• W2109290265 modified "2023-10-15" @default.
• W2109290265 title "Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas" @default.
• W2109290265 cites W140544558 @default.
• W2109290265 cites W172521639 @default.
• W2109290265 cites W1843877485 @default.
• W2109290265 cites W1964615535 @default.
• W2109290265 cites W1973760073 @default.
• W2109290265 cites W1982904703 @default.
• W2109290265 cites W1990620561 @default.
• W2109290265 cites W1998166148 @default.
• W2109290265 cites W2001493754 @default.
• W2109290265 cites W2020763802 @default.
• W2109290265 cites W2026901966 @default.
• W2109290265 cites W2046796218 @default.
• W2109290265 cites W2052123491 @default.
• W2109290265 cites W2077166252 @default.
• W2109290265 cites W2085277801 @default.
• W2109290265 cites W2093449268 @default.
• W2109290265 cites W2095081636 @default.
• W2109290265 cites W2101120359 @default.
• W2109290265 cites W2109996739 @default.
• W2109290265 cites W2124641104 @default.
• W2109290265 cites W2144727376 @default.
• W2109290265 cites W2166802949 @default.
• W2109290265 cites W2169293905 @default.
• W2109290265 cites W2170760045 @default.
• W2109290265 cites W4234177541 @default.
• W2109290265 cites W4294713489 @default.
• W2109290265 cites W4297936144 @default.
• W2109290265 cites W4360795059 @default.
• W2109290265 cites W4376595439 @default.
• W2109290265 doi "https://doi.org/10.1227/01.neu.0000215944.81730.18" @default.
• W2109290265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16723889" @default.
• W2109290265 hasPublicationYear "2006" @default.
• W2109290265 type Work @default.
• W2109290265 sameAs 2109290265 @default.
• W2109290265 citedByCount "98" @default.
• W2109290265 countsByYear W21092902652012 @default.
• W2109290265 countsByYear W21092902652013 @default.
• W2109290265 countsByYear W21092902652014 @default.
• W2109290265 countsByYear W21092902652015 @default.
• W2109290265 countsByYear W21092902652016 @default.
• W2109290265 countsByYear W21092902652018 @default.
• W2109290265 countsByYear W21092902652019 @default.
• W2109290265 countsByYear W21092902652021 @default.
• W2109290265 countsByYear W21092902652022 @default.
• W2109290265 countsByYear W21092902652023 @default.
• W2109290265 crossrefType "journal-article" @default.
• W2109290265 hasAuthorship W2109290265A5014244649 @default.
• W2109290265 hasAuthorship W2109290265A5015059017 @default.
• W2109290265 hasAuthorship W2109290265A5021588104 @default.
• W2109290265 hasAuthorship W2109290265A5024526307 @default.
• W2109290265 hasAuthorship W2109290265A5026110145 @default.
• W2109290265 hasAuthorship W2109290265A5052171046 @default.
• W2109290265 hasAuthorship W2109290265A5053547123 @default.
• W2109290265 hasConcept C10515644 @default.
• W2109290265 hasConcept C126838900 @default.
• W2109290265 hasConcept C141071460 @default.
• W2109290265 hasConcept C142724271 @default.
• W2109290265 hasConcept C143409427 @default.
• W2109290265 hasConcept C146957229 @default.
• W2109290265 hasConcept C2776694085 @default.
• W2109290265 hasConcept C2780739268 @default.
• W2109290265 hasConcept C2989005 @default.
• W2109290265 hasConcept C50382708 @default.
• W2109290265 hasConcept C544855455 @default.
• W2109290265 hasConcept C66339696 @default.
• W2109290265 hasConcept C71924100 @default.
• W2109290265 hasConceptScore W2109290265C10515644 @default.
• W2109290265 hasConceptScore W2109290265C126838900 @default.
• W2109290265 hasConceptScore W2109290265C141071460 @default.
• W2109290265 hasConceptScore W2109290265C142724271 @default.
• W2109290265 hasConceptScore W2109290265C143409427 @default.
• W2109290265 hasConceptScore W2109290265C146957229 @default.
• W2109290265 hasConceptScore W2109290265C2776694085 @default.
• W2109290265 hasConceptScore W2109290265C2780739268 @default.
• W2109290265 hasConceptScore W2109290265C2989005 @default.
• W2109290265 hasConceptScore W2109290265C50382708 @default.
• W2109290265 hasConceptScore W2109290265C544855455 @default.
• W2109290265 hasConceptScore W2109290265C66339696 @default.
• W2109290265 hasConceptScore W2109290265C71924100 @default.
• W2109290265 hasIssue "6" @default.
• W2109290265 hasLocation W21092902651 @default.
• W2109290265 hasLocation W21092902652 @default.
• W2109290265 hasOpenAccess W2109290265 @default.
• W2109290265 hasPrimaryLocation W21092902651 @default.
• W2109290265 hasRelatedWork W1554732404 @default.
• W2109290265 hasRelatedWork W1593574816 @default.

• next